Clinical Trial Update: Evaluating the Effects of Selective Treatment Utilizing Flex-dosing for Unresectable HCC With Y90 SIR-Spheres

View source ↗

Summary

A completed clinical trial assessed selective flex-dosing using Y-90 SIR-Spheres for unresectable hepatocellular carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• SIR-Spheres Y-90 (yttrium-90 resin microspheres)

Snippet

Sponsor: Methodist Health System | Conditions: Hepatocellular Carcinoma | Status: COMPLETED